Retatrutide Near Me: 300 Units Ship, Zero Sold Locally

Local results for an unapproved compound fall into five recognisable groups. Only the last one can supply anything, and it is not local.

Rows one to three are legitimate businesses answering a different question. Row four is the one worth walking away from. Row five is the answer, and its address is irrelevant.

Dispensing requires an approved product. A marketing authorisation, approved labelling and a product code are what let a pharmacy system recognise a medicine and a prescriber authorise it. Retatrutide has none of these in the United States, the European Union or the United Kingdom.

Compounding does not provide a way round that, and this is the point most local listings quietly depend on. Under the US framework, a bulk drug substance generally has to be a component of an approved drug, appear in a USP or National Formulary monograph, or sit on the FDA bulks list before a pharmacy may compound with it. Retatrutide satisfies none of the three, and the FDA's compounding framework sets out why that list exists.

There is a second wall behind it. A compounded preparation is made against a prescription for a named patient, and no prescriber can lawfully write a prescription for a compound with no authorisation. Even a pharmacy willing to try would need a prescription that cannot exist.

So an operation advertising retatrutide locally is doing one of two things. It is describing a different compound under a name that gets more searches, or it is selling grey-market material outside the framework it appears to work within. Our regulatory explainer covers the distinction in detail.

Clinics appearing for this search are usually running real weight-management programmes, and it is worth being clear about what those contain, because for many people it is the better answer.

Semaglutide and tirzepatide both hold marketing authorisations, both have published trial programmes, and both can be prescribed, dispensed and monitored by someone accountable for the outcome. A clinic can also supply the things a vial cannot: baseline measurements, follow-up, and a clinician to call. Our GLP-1 medications overview and weight-loss injections guide cover that side, and the tirzepatide dosage reference covers the arithmetic on the authorised product.

What no clinic can offer is retatrutide itself. If a programme names it in marketing material, ask which product will actually be dispensed, what its authorisation is, and what appears on the label. A clear answer usually names a different molecule.

Compounded GLP-1 preparations sit in between and are their own subject. They are not retatrutide either, and the same question applies: which substance, compounded under what authority.

The supply route is a research-chemical supplier shipping lyophilised vials labelled for laboratory use only. No prescription is requested because none exists to request, and the material is sold as a reagent rather than as a medicine.

Two vial sizes are listed. The 10 mg R-10 is $49.50 with the code PEPTIDEDECK, which is $4.95 per milligram. The 30 mg R-30 is $125.00, or $4.17 per milligram, about 16% cheaper on the same compound. A single 10 mg vial sits well below the $250 free-shipping line, so budget for carriage on a small first order.

Reconstitution decides the rest. A 30 mg vial made up with 3 mL of bacteriostatic water is 10 mg/mL, giving 300 graduations on a U-100 barrel where 10 units holds 1 mg and each unit costs $0.42. A 10 mg vial with 2 mL is 5 mg/mL, giving 200 graduations where 10 units holds 500 mcg. The calculator runs any combination, and the reconstitution guide covers diluent choice.

Our channel comparison goes through the alternatives to a domestic research supplier and why most of them fail on evidence rather than on price.

Put the two side by side on the numbers a buyer needs, and the comparison resolves itself before price is even reached.

Five of those six rows are blank on the local side, and the blanks are the finding. This is not a comparison where one option is more expensive. It is a comparison where only one option produces numbers at all, and an offer you cannot divide is an offer you cannot price.

The certificate row is the one that decides the others. Ascension publishes two third-party certificates per batch, from Kovera Labs covering batches 03-05260628 and 43-05260628, tested 26 May 2026, and from MZ Biolabs covering batches 03-01260229 and 43-01260229, tested 6 February 2026. A milligram figure with no certificate behind it is an input you should not put into any calculation.

Distance is the wrong unit for this search. What a buyer wants is time to hand, and dispatch policy governs that far more than geography does.

Ascension publishes same-day dispatch on orders placed before 2pm CST, Monday to Saturday. So an order at 1:45pm on a Tuesday goes out Tuesday; one at 2:15pm goes out Wednesday; one at 2:15pm on a Saturday waits for Monday. After handover the carrier's clock takes over, and a domestic parcel typically moves in days.

Set that against the local option honestly. A clinic three miles away that cannot lawfully hand you the compound is not closer, it is unavailable. A warehouse a thousand miles away that packs your vial this afternoon is two or three days away. On this compound, the second one is nearer in every sense that matters.

Storage is the part proximity genuinely affects, and only briefly. A parcel that sits in a hot vehicle for a day is a handling question rather than a distance question, so plan for delivery to somewhere it will be received. Our storage guide covers lyophilised and reconstituted material.

If something is being offered nearby anyway, these six signals are worth more than any impression of the seller.

• A premixed pen or cartridge labelled retatrutide. No authorised presentation exists, so a pen is a repackaging decision made by someone with no label to follow.
• A strength quoted in units or clicks rather than milligrams. Units measure volume, not mass. Without a mg/mL figure the number is meaningless.
• No batch code on the vial, or a code that matches no published certificate. That makes the strength unverifiable, and the strength is the input everything else divides by.
• Cash or peer-to-peer app payment with no invoice. No paper trail also means no dispute rights.
• Human-use instructions attached to the sale. A seller giving dosing guidance for an unapproved compound has stepped well outside the research framing that makes the sale lawful.
• A claim that it is FDA approved or pharmaceutical grade. No approved retatrutide product exists, so the first claim is false on its face and the second is marketing rather than a standard.

The compound is genuinely interesting, which is why these offers find buyers. The Phase 2 trial in the New England Journal of Medicine reported about 24% mean weight reduction at 48 weeks on the 12 mg arm, and Phase 3 is still running. None of that makes a vial handed over in a car park a verified vial.